Vasectomy News and Research

RSS
A vasectomy is a surgical procedure that makes a man sterile, or unable to get a woman pregnant. It is generally considered to be at least as effective as female sterilization and is simpler to perform, safer, and less costly. A vasectomy is done by blocking the tube, called the vas deferens, through which sperm normally pass from each testicle on the way to the seminal vesicle, forming semen.
Chesapeake Urology for Kids introduced for pediatric care

Chesapeake Urology for Kids introduced for pediatric care

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Adverse fetal growth, exposure to maternal smoking correlated with lower measures of sperm quality

Adverse fetal growth, exposure to maternal smoking correlated with lower measures of sperm quality

European Commission amends marketing authorisation for Celgene's REVLIMID

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Roundup: Abortion bill heads to Mich. Gov's desk; Calif. health care special session priorities; Nurse practitioner role debated in Minn.

Roundup: Abortion bill heads to Mich. Gov's desk; Calif. health care special session priorities; Nurse practitioner role debated in Minn.

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

Roughly two in five women in the U.S. do not use any form of birth control: Survey

Roughly two in five women in the U.S. do not use any form of birth control: Survey

WHO commits to fast-track assessment of new and existing quality contraceptives

WHO commits to fast-track assessment of new and existing quality contraceptives

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

UM hosts symposium on next generation characterization tools for therapeutic proteins

UM hosts symposium on next generation characterization tools for therapeutic proteins

Ga. vasectomy bill goes viral

Ga. vasectomy bill goes viral

New research gains increased respect for contraceptive method

New research gains increased respect for contraceptive method

FDA approves Genentech's Erivedge for treatment of BCC

FDA approves Genentech's Erivedge for treatment of BCC

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.